BioSpace News Archive

The authors concluded that “These results support the notion that higher doses of naloxone result in greater bioavailability, which may be required for reversal due to the more potent synthetic opioids such as fentanyl.”

The Company is scheduled to present on Thursday, November 21, 2019 at 9:20 a.m. GMT

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), will be presented today at the American Heart Association’s (AHA) Scientific Sessions 2019 in Philadelphia

Goal reached one year early thanks to generosity of associates, clients and communities

Sikich Investment Banking served as the exclusive sell-side adviser to ORFLO Technologies.

Fast recipe development combined with improved mass production yield and methodology for quality certification of AM parts, existing and new materials and processes, will be defined and demonstrated.

Program Provides Access and Affordability for Patients Seeking Treatment for Acute Migraine

Collective partners with Kno2 to enable physician and care team members with high-value clinical insights at the point of care to inform care decisions

On November 22, for the first time, the Mateon team will present a poster regarding the predictors of response and treatment outcome.

E-Commerce Site: www.taurigum.com